Forget McGregor-Mayweather. The biotech world has been waiting for months to hear about Novartis’ pricing decision for Kymriah, its just-approved CAR-T therapy for cancer. That interest turned into anxiety days earlier when Gilead announced its purchase of Kite, given that Kite is expected to ...